Introduction {#s0005}
============

Autoimmune bullous diseases (AIBD) are organ-specific autoimmune disorders of the skin and mucous membranes. Target antigens in AIBD are located in the adhesion proteins between epidermal keratinocytes (pemphigus group of diseases) or at the dermoepidermal junction (pemphigoid group of diseases; [@bb0095], [@bb0030]). Clinical entities in both disease groups have been described on the basis of identification of target autoantigens.

In contrast, dermatomyositis (DM) is a heterogeneous autoimmune disease that affects primarily the skin and muscles, with potential lung, joint, or cardiac involvement. DM can be associated with systemic lupus erythematosus, rheumatoid arthritis, secondary Sjogren's syndrome, and solid organ tumors, including the lung, breast, ovarian, and gastric neoplasms ([@bb0110]).

It is common for multiple autoimmune diseases to occur in the same patient; however, AIBDs do not commonly associate with DM ([Table 1](#tbl0005){ref-type="table"}; [@bb0075], [@bb0080], [@bb0095]). There are limited reports on this association, which may be attributed to misdiagnosis, underreporting, or true rarity of association. Herein, we report on two additional cases of AIBD associated with DM---one patient with pemphigus vulgaris (PV) and another with mucous membrane pemphigoid (MMP)---along with a review of the related literature.Table 1Diseases associated with autoimmune bullous diseases and dermatomyositisTable 1DiseaseAssociated diseasesPemphigus vulgaris/foliaceus ([@bb0010], [@bb0020], [@bb0035], [@bb0070], [@bb0085], [@bb0115])Autoimmune thyroid disease, rheumatoid arthritis, type 1 diabetes, psoriasis, Parkinson's disease, hematologic malignanciesBullous pemphigoid ([@bb0070], [@bb0145])Psoriasis, neurologic disorders, psychiatric conditions, solid or hematological malignanciesMucous membrane pemphigoid ([@bb0070])Solid malignancies (anti--laminin-332 MMP), rheumatoid arthritis, systemic lupus erythematosusAnti-p200 pemphigoid ([@bb0080])PsoriasisEpidermolysis bullosa acquisita ([@bb0080])Inflammatory bowel disease, hematological malignancies, systemic lupus erythematosusLinear immunoglobulin A dermatosis ([@bb0080])Lymphoproliferative diseases, ulcerative colitisDermatitis herpetiformis ([@bb0060], [@bb0080])Autoimmune thyroiditis, type 1 diabetes, lupus erythematosus, Sjögren syndrome, vitiligo, primary biliary cirrhosis, pernicious anemia, alopecia areata, neuropathiesDermatomyositis ([@bb0150])Systemic lupus erythematosus, rheumatoid arthritis, Sjogren syndrome, solid organ tumors (lung, breast, ovarian, and gastric neoplasms)

Case 1 {#s0010}
======

A 51-year-old woman presented with a history of PV, which was first diagnosed 8 months earlier. She initially had erosions on the tongue, buccal mucosa, and pharynx, as well as blisters on her trunk. Her medical history was relevant for Hashimoto's thyroiditis, idiopathic trace proteinuria, facial erythema, diffuse nonscarring alopecia, and multifocal arthralgias. Notable laboratory test results included antinuclear antibody 1:160, + Sjögren\'s syndrome antibodies, and + anti-thyroperoxidase and + anti-thyroglobulin antibodies. Testing on skin biopsies from the breast and back showed typical suprabasal acantholysis with tombstone appearance of basal cells.

The patient was treated with low-dose prednisone, but control of the disease was not achieved, and the patient was referred with recalcitrant oral and pharynx erosions. At that time, the patient reported dysphagia, proximal muscle weakness, myalgias, and arthralgias. Upon examination, subtle clinical findings were suggestive of DM, including dilated capillary loops and hemorrhage on the proximal nail folds ([Fig. 1](#fig0005){ref-type="fig"}), poikilodermatous changes on the neck, and faint erythema and hyperpigmentation over the extensor elbows and dorsal knuckles (Gottron's sign). Additional workup showed normal creatinine kinase and aldolase levels. A myositis panel demonstrated + Sjögren\'s syndrome antibodies-60.Fig. 1Dilated capillary loops and hemorrhage on the proximal nail folds (Case 1).Fig. 1

Case 2 {#s0015}
======

An 82-year-old man presented with MMP limited to the oral mucosa, which was first diagnosed 14 years earlier (in 2004) through gingival biopsy testing. He was initially treated with dapsone (50-100 mg/day), prednisone (10-30 mg/day), and topical clobetasol. Mycophenolate mofetil was added in 2006, allowing taper of systemic corticosteroids. Five years ago, due to disease quiescence, mycophenolate mofetil was gradually tapered and discontinued in November 2013. The patient was maintained on a combination of dapsone and topical clobetasol. In August 2014, he was noted to have crackling by chest auscultation and low oxygen saturation. He was referred to pulmonology, diagnosed with chronic obstructive pulmonary disease, and initiated on overnight oxygen supplementation.

Over the next 2 years, the patient had progressive shortness of breath, nonproductive cough, exertional muscle fatigue, and increased oxygen requirements. Pulmonary function testing was notable for forced expiratory volume in 1 second/forced vital capacity of 71% predicted and a diffusion capacity of carbon monoxide of 42% predicted. A chest computed tomography scan demonstrated bibasilar reticulation, septal thickening, and centrilobular emphysema, consistent with mixed pulmonary fibrosis and emphysema. In October 2017, due to worsening pulmonary symptoms, the patient was initiated on prednisone 30 mg.

Upon examination, dilated capillaries with dropout in the proximal nail fold and prominent erythema on the extensor elbows and overlying the knuckles (Gottron's sign) were noted ([Fig. 2](#fig0010){ref-type="fig"}). A skin biopsy of the extensor elbow demonstrated vascular ectasia with mild perivascular lymphocytic infiltrate and scattered dyskeratotic cells at the dermo-epidermal junction.Fig. 2Prominent erythema on the extensor elbows and overlying the knuckles (Gottron's sign) (Case 2).Fig. 2

Laboratory test results of both cases are presented in [Table 2](#tbl0010){ref-type="table"}.Table 2Diagnostic examination results of present casesTable 2Histopath of bullous lesionDIFELISAHistopath of inflammatory skin lesion that could be DMPFTsHLA**Case 1**\
(PV and classic DM)Acantholytic dermatosis (Right breast, 4/26/2018)IgG and C3 deposition intercellularly (left upper back,\
4/26/2018)Dsg 1: 126.4075\
(\> 36)\
Dsg 3: 59.28889\
(\> 37)\
(10/05/2018)N/AOrder activeN/A**Case 2**\
(MMP and DM)Consistent with pemphigoid\
(right buccal and gingival mucosa -2004)N/AVascular ectasia and perivascular inflammation, with rare dyskeratotic cells at the dermoepidermal junction, compatible with connective tissue disorder\
(Right elbow, 6/12/2018)Mild combined restriction and obstruction, with severely reduced diffusing capacity of the lungs for carbon monoxide\
\
8/24/2018\
Pulm: combined pulmonary fibrosis and emphysems (has smoking history also).\
\
Only fulfilled probable UIP (ILD). Lung biopsy is definitive.N/A[^1]

Discussion {#s0020}
==========

The first case report of any association of AIBD with DM was a case of dermatitis herpetiformis (DH) in a 67-year-old woman in whom DM preceded the manifestations of DH by 4 years ([@bb0135]). Eleven subsequent cases of AIBD associated with DM have since been reported. In total, four cases of bullous pemphigoid (BP), three cases of DH, two cases of PV, two cases of pemphigus foliaceus, and one case of linear immunoglobulin (Ig) A dermatosis have been reported ([Table 3](#tbl0015){ref-type="table"}; [@bb0015], [@bb0020], [@bb0035], [@bb0045], [@bb0050], [@bb0060], [@bb0085], [@bb0115], [@bb0120], [@bb0135], [@bb0145]).Table 3Dermatomyositis in association with autoimmune blistering diseases in the present literatureTable 3CaseCitationAIBDAge, yearsSexTiming of DM diagnosisDM typeTreatmentAssociated malignancy1[@bb0085]PF11Male2 years earlierJuvenilePrednisolone; hydroxychloroquine; cyclosporine; methotrexate; cyclophosphamideNone2[@bb0020]PV76Female40 months earlierClassicPrednisolone; methotrexateNone3[@bb0115]PV36Female4 years laterAmyopathicPrednisolone; dapsone; chloroquine; methotrexate; colchicine; celecoxibNone4[@bb0035]PF39Female29 months earlierAmyopathicTopical steroidal agentsNone**5Present casePV51Female8 months laterClassicPrednisoneNone**6[@bb0050]BP65MSimultaneouslyClassicPrednisolone; azathioprine7[@bb0120]BP70Male8 months laterClassicPrednisolone; methotrexate; minocyclineNone8[@bb0145]BP81FemaleSimultaneouslyClassicTopical steroidal agentsColon carcinoma9[@bb0045]BP69FemaleSimultaneouslyAmyopathic + ILDPrednisolone; rituximabGastric MALT lymphoma**10Present caseMMP82Male5 years laterAmyopathic + ILDPrednisone; dapsone; mycophenolate mofetilNone**11[@bb0015]Linear IgA dermatosis56FemaleSimultaneouslyClassicDapsone; prednisoloneNone12[@bb0135]DH67Female3 years earlierClassicNone13[@bb0060]DH34Male7 years laterClassicDapsone; prednisoloneNone14[@bb0060]DH33Male4 years laterClassicNone[^2]

Among all 14 cases, there was no sex predominance (six men, eight women). DM was diagnosed before (four of 14 patients), simultaneous with (four of 14 patients), or after (six of 14 patients) the diagnosis of AIBD. Most cases had features of classic DM (nine of 14 patients). No muscle involvement was reported in four of 14 cases (amyopathic DM). Associated malignancy was reported only in two cases of BP (colon carcinoma and gastric mucosa-associated lymphoid tissue lymphoma; [@bb0045], [@bb0145]).

In the present literature review, none of the 14 patients with AIBD and DM had mucosal lesions attributed to DM. In DM, mucosal involvement, clinically represented as dysphagia, is reported in cohorts of patients with anti-nuclear matrix protein 2 DM and anti-small ubiquitin-like modifier-activating enzyme 1/2 autoantibody-positive DM ([@bb0140]).

AIBD-associated interstitial lung disease (ILD) is rare, and linked with relapse and treatment-resistant AIBD ([@bb0125]). In these cases, ILD has an improved response to systemic corticosteroids and a relatively better prognosis when compared with RA- or DM-associated ILD ([@bb0010], [@bb0155]).

In these patients, the clinical differential diagnosis should always include the pulmonary disease that accompanies paraneoplastic pemphigus/paraneoplastic multiorgan syndrome and represents a serious cause of morbidity/mortality. The mechanism of AIBD-associated ILD is unknown. There is speculation that cell adhesion proteins in the respiratory epithelial cells are similar to cutaneous desmosomes, or hemidesmosomes may cross-react with skin-directed autoantibodies. [@bb0155] described a case of BP-associated interstitial pneumonia in which linear deposition of IgG and C3 along the basement membrane of the alveoli was shown by direct immunofluorescence. Whether ILD is a pulmonary manifestation of BP requires further investigation.

Both AIBD and DM may affect genetically predisposed individuals. The most common human leukocyte antigen haplotypes associated with AIBD are summarized in [Table 4](#tbl0020){ref-type="table"} ([@bb0065], [@bb0075], [@bb0080], [@bb0095], [@bb0110]). Similar human leukocyte antigen associations have been observed in DM and BP, MMP, and DH.Table 4Human leukocyte antigen associations in autoimmune bullous diseases and dermatomyositisTable 4DiseaseHuman leukocyte antigen associationPemphigus vulgaris/foliaceusDRB1\*0402, DRB1\*1401, DQB1\*0302 (Caucasians)\
DRB1\*14, DQB1\*0503 (Japanese)\
A10, B38Bullous pemphigoidDQB1\*0301, DRB1\*04, DRB1\*1101\
DQB1\*0302 (Japanese)Mucous membrane pemphigoidDQB1\*0301, DRB1\*04, DRB1\*11, DRB1\*1503Epidermolysis bullosa acquisitaDR2 (African Americans)\
DRB1\*1503, DRB1\*13 (Koreans)Linear immunoglobulin A dermatosisB8, Cw7, DR3.3Dermatitis herpetiformisDQ2 with DQA1\* 0501/DQB1\*0201, DQA1\*0501, DQB1\*0202, DRB1\*03, DRB1\*05/07\
DQ8 with DQA1\*0301/DQB1\*0302, DRB1\*4DermatomyositisDRB1\*0301 or DQA1\*0501 (Caucasians)\
B7, DRB1\*0301 (Asians)\
DQA1\*0501 (anti-Jo-1)\
DRB1\*07 or DQA\*0201 (anti-Mi-2)

Potential environmental triggers of both AIBD and DM have not been conclusively identified ([@bb0020]). Some authors hypothesize that continuous epidermal damage from DM or sun-induced photodamage might unmask previously immunoprivileged antigens (i.e., epitope spreading phenomenon), leading to further autoimmune responses ([@bb0035], [@bb0050], [@bb0120]). However, the temporal relationship is not always consistent with this mechanism, particularly when blisters are present at the onset of DM.

Drug-related triggers may contribute in some cases because both DM and AIBD have been associated with medication exposure ([Table 5](#tbl0025){ref-type="table"}; [@bb0025], [@bb0040], [@bb0055], [@bb0100], [@bb0105], [@bb0130]). Medications may act as haptens, modify the antigenicity of structural proteins, or affect the immune tolerance against components of the adhesion structures among keratinocytes or at the dermoepidermal junction ([@bb0025]). None of the presented cases had a history of environmental and/or drug triggers.Table 5Drugs associated with autoimmune bullous diseases and dermatomyositisTable 5DiseaseAssociated medicationsPemphigus vulgaris/foliaceusCaptopril, penicillamine, gold, aspirin, rifampin, levodopa, calcium channel blockers, sulfasalazineBullous pemphigoidThiol-containing anti-hypertensive drugs, diuretics (especially furosemide), gliptins, penicillamine, sulfasalazine, phenacetin, nonsteroidal antiinflammatory drugs, salicylates, anti-tumor necrosis factor agents, vaccinesMucous membrane pemphigoidGliptins, diphtheria-tetanus vaccination, atenolol, nonsteroidal antiinflammatory drugsLinear immunoglobulin A dermatosisVancomycin, captopril, amiodarone, penicillins, cephalosporins, diclofenac, captopril, glibenclamideEpidermolysis bullosa acquisitaVancomycinDermatitis herpetiformisAnti-tumor necrosis factor agents, gonadotropin-releasing hormone analog, leuprolideDermatomyositisHydroxyurea, penicillamine, statins, cyclophosphamide, Bacillus Calmette--Guérin vaccine, ipilimumab, proton pump inhibitors, lacosamide, capecitabine, anti-tumor necrosis factor agents, interferon-alfpha, nonsteroidal antiinflammatory drugs, zoledronic acid

Paraneoplastic processes may be linked to autoimmunity in both AIBD and DM ([@bb0005], [@bb0070]). In BP, MMP, and linear IgA dermatosis, autoantibodies directed against epidermal keratinocyte adhesion proteins may cross-react with antibodies against tumor antigens. Another hypothesis is that the tumor may produce antigens that directly damage the dermoepidermal junction, leading to the formation of anti--basement membrane zone autoantibody production ([@bb0005], [@bb0070]). In DM, there may be expression of common autoantigens between tumor and muscle tissue, with immune response directed against tumor cells that also targets similar autoantigens in muscle tissue (i.e., molecular mimicry), resulting in muscle damage ([@bb0090], [@bb0150]). In the reported cases of AIBD associated with DM, a paraneoplastic process was observed in just two of 14 patients.

Conclusion {#s0025}
==========

Dermatologists must be vigilant for a second autoimmune disease in patients with AIBD that may have therapeutic implications. These presentations may be subtle and insidious at the time of onset.
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[^1]: DIF, direct immunofluorescence; DM, dermatomyositis; Dsg, desmoglein; ELISA, enzyme-linked immunosorbent assay; DIF, HLA, human leukocyte antigen; Ig, immunoglobulin; ILD, interstitial lung disease, MMP, mucous membrane pemphigoid; N/A, not available; PFT, pulmonary function testing; PV, pemphigus vulgaris; UIP, usual interstitial pneumonia

[^2]: AIBD, autoimmune bullous disease; BP, bullous pemphigoid; DH, dermatitis herpetiformis; DM, dermatomyositis; Ig, immunoglobulin; ILD, interstitial lung disease; MALT, mucosa-associated lymphoid tissue; MMP, mucous membrane pemphigoid; PF, pemphigus foliaceus; PV, pemphigus vulgaris
